Global Peptic Ulcer Drugs Market 2017-2025: Focus on Antibiotics, PPIs, H2 Receptor Antagonists, Gastric Mucosal Protective Drugs, Antacids and Prostaglandin Agonists

The global Peptic ulcer drugs market was valued at US$ 4.63 Bn in 2016, and is expected to reach US$ 5.92 Bn by 2025, expanding at a CAGR of 2.8% from 2017 to 2025.For the purpose of study peptic ulcer drugs market is segmented on the basis of drug class such as antibiotics, proton pump inhibitors (PPIs), H2 receptor antagonists, gastric mucosal protective drugs, antacids and prostaglandin agonists. It is observed that currently, PPIs is major revenue generating segment because these drugs are recommended as a first line treatment for treatment of peptic ulcers caused by H. pylori bacterial infection and NSAIDs, due to its ability to reduce acid secretion.

The global Peptic ulcer drugs market was valued at US$ 4.63 Bn in 2016, and is expected to reach US$ 5.92 Bn by 2025, expanding at a CAGR of 2.8% from 2017 to 2025.

For the purpose of study peptic ulcer drugs market is segmented on the basis of drug class such as antibiotics, proton pump inhibitors (PPIs), H2 receptor antagonists, gastric mucosal protective drugs, antacids and prostaglandin agonists. It is observed that currently, PPIs is major revenue generating segment because these drugs are recommended as a first line treatment for treatment of peptic ulcers caused by H. pylori bacterial infection and NSAIDs, due to its ability to reduce acid secretion.

In 2016, North America dominated the peptic ulcer drugs market in terms of revenue and it is anticipated that it will show steady growth during forecast period. According to Centers for Disease Control and Prevention (CDC) peptic ulcer affects more than 6 million population in the United States annually. Factors such as large number of affected population, higher cost of treatment medication, improved diagnostic technique and upsurge in funding by the government agencies in healthcare system are driving the market growth in North America.

On the other hand, Asia Pacific will show highest growth rate during forecast period due to changing lifestyle, higher number of affected population, increasing rate of smoking and rising healthcare awareness would expected to drive growth of peptic ulcers drugs market globally.

The peptic ulcer drugs market is observed to be highly competitive and comprises large number of players. However, the market is currently dominated by few players such as Abbott Laboratories, AstraZeneca plc, Cadila Healthcare Ltd, Daewoong Pharmaceuticals, Eisai Co. Ltd, PharmaKing Co. Ltd, Taiho Pharmaceutical (A Otsuka Holdings), Takeda Pharmaceutical, Yuhan Corporation and other.

Key Market Movements:

Key Topics Covered:

Chapter 1 Preface
1.1 Report Description
1.2 Research Scope
1.3 Research Methodology

Chapter 2 Executive Summary
2.1 Global Peptic Ulcer Drugs Market Snapshot
2.2 Global Peptic Ulcer Drugs Market, Drug Class
2.3 Global Peptic Ulcer Drugs Market Share, by Geography, 2016 (Value %)

Chapter 3 Peptic Ulcer Drugs Market Analysis
3.1 Global Peptic Ulcer Drugs Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Pipeline Analysis in Peptic Ulcer Drugs Market
3.4 Global Epidemiology Data for Peptic Ulcer
3.5 Attractive Investment Proposition
3.6 Competitive Landscape of Key Players in Peptic Ulcer Drugs Market

Chapter 4 Global Peptic Ulcer Drugs Market, by Drug Class
4.1 Overview
4.2 Top 3 Countries
4.3 Antibiotics
4.4 Proton Pump Inhibitors (PPIs)
4.5 H2 Receptor Antagonists
4.6 Gastric Mucosal Protective Drugs
4.7 Antacids
4.8 Prostaglandin Agonists

Chapter 5 Global Peptic Ulcer Drugs Market, By Geography

Chapter 6 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/q8z3wp/global_peptic?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716